Patents Issued in March 4, 2014
-
Patent number: 8664341Abstract: Embodiments include vinylbenzyl ethers of polycyclopentadiene polyphenol that can be obtained by reacting a polycyclopentadiene polyphenol with a vinylbenzyl halide. Embodiments also include thermosettable compositions including the vinylbenzyl ethers of a polycyclopentadiene polyphenol and products obtained by curing the thermosettable compositions. Formula (I).Type: GrantFiled: April 21, 2011Date of Patent: March 4, 2014Assignee: Dow Global Technologies, LLCInventor: Robert E. Hefner, Jr.
-
Patent number: 8664342Abstract: Process for introducing a solid polymerization catalyst into a gas-phase fluidized bed using an injection device having an inner tube of internal cross-sectional area of 10 to 100 mm2 and an outer tube forming an annulus around the inner tube with a cross-sectional area of 1 to 10 times the internal cross-sectional area of the inner tube. The polymerization catalyst and a carrier gas are passed through the inner tube and into the gas-phase fluidized bed at a carrier gas linear velocity of 4 to 14 m/s and a carrier gas mass flow rate of 10-35 kg/h. A shielding gas is passed through the outer tube and into the gas-phase fluidized bed at a linear velocity of 1 to 10 times the carrier gas linear velocity through the inner tube and at a mass flow rate of 100-500 kg/h. No cooled recycle process gas is provided to the injection device.Type: GrantFiled: September 21, 2009Date of Patent: March 4, 2014Assignee: Ineos Commercial Services UK LimitedInventors: Bruno Bordais, Christohper James Kemp, Jose Andre Laille, Willy Lemesle
-
Patent number: 8664343Abstract: A polymerization catalyst composition for preparing cis 1,4-polydienes is provided. The catalyst composition comprises (a) a metal-containing compound, said metal being a transition metal or a lanthanide metal; (b) a carbene, (c) an alkylating agent, and optionally (d) a halogen-containing compound with the proviso that the halogen-containing compound must be present when none of the metal-containing compound and the alkylating agent contain a labile halogen atom. Also provided is a process for producing a polydiene comprising reacting a conjugated diene in the presence of the polymerization catalyst composition.Type: GrantFiled: June 9, 2009Date of Patent: March 4, 2014Assignee: Bridgestone CorporationInventors: Zengquan Qin, Jason T. Poulton
-
Patent number: 8664344Abstract: Process for the preparation of polybutadiene effected by the polymerization of butadiene in an aliphatic and/or cyclo-aliphatic solvent in the presence of a catalytic system prepared in situ which comprises: (i) a carboxylate of neodymium soluble in the process solvent containing a variable quantity of water, the H2O/Nd molar ratio ranging from 0.001/1 to 0.50/1; (ii) an alkyl compound of aluminum; (iii) an alkyl compound of aluminum in which at least one bond of Al consists of an Al—Cl bond; The total Al/Nd molar ratio ranging from 4/1 to 12/1, and the Cl/Nd molar ratio ranging from 2/1 to 6/1.Type: GrantFiled: March 19, 2009Date of Patent: March 4, 2014Assignee: Polimeri Europa S.p.A.Inventors: Gian Tommaso Viola, Marianna Zinna
-
Patent number: 8664345Abstract: This invention describes a process for the preparation of a catalytic composition that can be used for oligomerization, codimerization, or polymerization of olefins. This invention also describes the catalytic composition that can be obtained by said process for the preparation and its use for oligomerization, codimerization, or polymerization of olefins.Type: GrantFiled: October 13, 2009Date of Patent: March 4, 2014Assignee: IFP Energies nouvellesInventors: Claudine Rangheard, Helene Olivier-Bourbigou, David Proriol
-
Patent number: 8664346Abstract: A targeted molecular weight of an organopolysiloxane is obtained in a two stage hydrolysis by hydrolyzing a chlorosilane with from 0.002 to 0.6 mol of water in a first step in the presence of alcohol, in which the pressure and/or temperature are adjusted such that following further hydrolysis in a second step, the targeted molecular weight is obtained.Type: GrantFiled: January 22, 2008Date of Patent: March 4, 2014Assignee: Wacker Chemie AGInventor: Gerhard Staiger
-
Patent number: 8664347Abstract: Silicone-polyether block copolymers are disclosed, having the average formula: R4R12Si(OR52Si)m{[R2O(CqH2qO)pR2R12Si(OR52Si)k]nR2O(CqH2qO)pR2R12Si)m}hOSiR12R4 wherein R1 is C1-C10 hydrocarbyl; R2 is C1-C10 hydrocarbylene; R3 is R1 or H; R4 is —R2—NR32 or —R2—NR3—R2—NR32; R5 is R1 or R4; h is 1 to 100; k is 2 to 500; m is 2 to 500; n is 0 to 30; p is 2 to 120; and q is 2 to 4. The silicone-polyether block copolymers comprise two terminal amine functionalities and may comprise varying degrees of pendent amine functionality. In a method for synthesizing linear silicone-polyether block copolymers of the above formula, a reaction mixture is formed by combining a polyether, an organosilicon component, an endblocking agent, and a catalyst. Thereupon, the reaction mixture is heated to produce a silicone-polyether block copolymer having at least one pendent amine functionality and a number-average molecular weight from 2000 to 500,000.Type: GrantFiled: April 6, 2011Date of Patent: March 4, 2014Assignee: Dow Corning CorporationInventors: Brian P. Deeth, John Joseph Kennan, Kevin Dale Lewis
-
Patent number: 8664348Abstract: New triaminophenol compositions and related compounds are disclosed, as are processes for their preparation and for the preparation of novel salts and diacid complexes from such compounds. Polymers prepared from these compositions can be made into high strength fiber, film, and tape and are useful in applications such as protective apparel, aircraft, automotive components, personal electronics, and sports equipment.Type: GrantFiled: December 21, 2010Date of Patent: March 4, 2014Assignee: E I du Pont de Nemours and CompanyInventors: Rajiv Dhawan, Joachim C Ritter, Frederick K Mallon, Steven R Allen, David J Rodini, Roger K Siemionko
-
Patent number: 8664349Abstract: The present invention relates to polycarbonate compositions and copolycarbonate compositions having improved optical properties, and to their production and their use for the production of shaped parts, and to shaped parts which can thereby be obtained, the compositions containing a polycarbonate or copolycarbonate which comprises bisphenol-A and at least one pair of a phosphorus compound having the oxidation number +3 and a phosphorus compound having the oxidation number +5, and the phosphorus compound having the oxidation state +5 in a pair respectively corresponding to the oxidized form of the phosphorus compound having the oxidation state +3 and the amount of more highly oxidized compound contained being less than that of the compound with the lower oxidation number.Type: GrantFiled: September 17, 2010Date of Patent: March 4, 2014Assignee: Bayer MaterialScience AGInventors: Rolf Wehrmann, Helmut-Werner Heuer, Anke Boumans
-
Patent number: 8664350Abstract: The invention relates to a composition containing a particulate solid, a plastic material and a compound. The invention further relates to novel compounds, and the use of the coupling agents.Type: GrantFiled: October 23, 2007Date of Patent: March 4, 2014Assignee: Lubrizol LimitedInventor: Dean Thetford
-
Patent number: 8664351Abstract: The present invention provides a biaxially oriented polyester film for a backsheet of solar batteries which exhibits a good hydrolysis resistance and a low haze. The present invention relates to a biaxially oriented polyester film for a backsheet of solar batteries, comprising titanium in an amount of not more than 20 ppm in terms of a titanium atom, phosphorus in an amount of not more than 70 ppm in terms of a phosphorus atom, and antimony in an amount of not more than 10 ppm in terms of an antimony atom; and having a carboxyl end group content of not more than 26 equivalents/t and an intrinsic viscosity of 0.65 to 0.90.Type: GrantFiled: January 13, 2011Date of Patent: March 4, 2014Assignee: Mitsubishi Plastics, Inc.Inventors: Koutarou Nozawa, Taku Aoike
-
Patent number: 8664352Abstract: A polyester polyol made from natural oil feedstocks is disclosed. Methods for making the polyol are also disclosed. The method comprises reacting hydroxylated fatty acid/alkyl esters with a multifunctional ester-reactive initiator compound to form the polyester polyol. In one embodiment, the hydroxylated fatty acid/alkyl esters are made by hydroxylating fatty acid/alkyl esters having up to ninety-five percent by weight monounsaturation.Type: GrantFiled: October 31, 2008Date of Patent: March 4, 2014Assignee: Cargill, IncorporatedInventors: Timothy Walter Abraham, Jeff J. Malsam
-
Patent number: 8664353Abstract: A process for purifying a polyol(per)fluoropolyether derivative [polyol (P)] from a mixture (M) of hydroxyl(per)fluoropolyether derivatives, such polyol (P) comprising one or more hydroxyl(per)fluoropolyether derivatives [PFPEs (OH)] comprising at least one (per)fluoropolyoxyalkylene chain (chain Rf) and at least one end-group having formula (t3): —CF2CH2OCH2CH(OH)CH2OCH2CH(OH)CH2OH, such mixture (M) comprising said polyol (P) and at least one hydroxyl(per)fluoropolyether derivative [PFPE (OH)] different from polyol (P) and comprising at least one chain Rf and at least one end-group selected from end-groups having formula (t1): —CF2CH2OH and formula (t2): —CF2CH2OCH2CH(OH)CH2OH.Type: GrantFiled: May 6, 2010Date of Patent: March 4, 2014Assignee: Solvay Solexis S.P.A.Inventors: Claudio Adolfo Pietro Tonelli, Graziano Giuseppe Vezzulli, Rosaldo Picozzi, Piero Gavezotti
-
Patent number: 8664354Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.Type: GrantFiled: July 31, 2013Date of Patent: March 4, 2014Assignee: Synergy Pharmaceuticals Inc.Inventor: Kunwar Shailubhai
-
Patent number: 8664355Abstract: It is provided a simple and efficient process for producing a large amount of protein in a cell-free protein synthesis system, through a continuous synthesis reaction over a long time using a linear DNA as a template. The continuous synthesis reaction is carried out for at least one hour with a cell-free protein synthesis system comprising an extract of Escherichia coli cells cultured at any temperature between 18° C. and 36° C., and a linear template DNA encoding the protein. The continuous protein synthesis system is preferably a dialysis system or a continuous flow system. The cell-free protein synthesis system by dialysis system comprises an internal dialysate comprising the extract and the linear template DNA, an external dialysate comprising a substrate solution for protein synthesis, and a dialysis membrane through which the substrate can be transferred.Type: GrantFiled: May 17, 2007Date of Patent: March 4, 2014Assignee: RikenInventors: Natsuko Matsuda, Takanori Kigawa, Shigeyuki Yokoyama
-
Patent number: 8664356Abstract: The invention provides compounds and methods, for example, to carry out organocatalytic Michael additions of aldehydes to cyclically constrained nitroethylene compounds catalyzed by a proline derivative to provide cyclically constrained ?-substituted-?-nitro-aldehydes. The reaction can be rendered enantioselective when a chiral pyrrolidine catalyst is used, allowing for Michael adducts in nearly optically pure form (e.g., 96 to >99% e.e.). The Michael adducts can bear a single substituent or dual substituents adjacent to the carbonyl. The Michael adducts can be efficiently converted to cyclically constrained protected ?-amino acid residues, which are essential for systematic conformational studies of ?-peptide foldamers. New methods are also provided to prepare other ?-amino acids and peptides. These new building blocks can be used to prepare foldamers, such as ?/?-peptide foldamers, that adopt specific helical conformations in solution and in the solid state.Type: GrantFiled: October 14, 2010Date of Patent: March 4, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Samuel Helmer Gellman, Li Guo, Michael Giuliano
-
Patent number: 8664357Abstract: According to the present invention, there is provided a process for the preparation of a first compound selected from peptides, oligonucleotides and peptide nucleic acids. The process comprises synthesizing the first compound and then separating the first compound formed in step (i) from a second compound, which is a reaction by-product of the synthesis of the first compound and/or an excess of a reagent used for the synthesis of a first compound by a process of diafiltration. The membrane used for the diafiltration process is stable in organic solvents and provides a rejection for the first compound which is greater than the rejection for the second compound.Type: GrantFiled: August 7, 2009Date of Patent: March 4, 2014Assignee: Imperial Innovations LimitedInventors: Andrew Guy Livingston, Ludmila Georgieva Peeva, Sheyung Wang Jerry So, Renato Campos Vasconceles, Robin John Leatherbarrow, Edward William Tate, Piers Robert James Gaffney
-
Patent number: 8664358Abstract: Methods are provided for predicting the presence, subtype and stage of ovarian cancer, as well as for assessing the therapeutic efficacy of a cancer treatment and determining whether a subject potentially is developing cancer. Associated test kits, computer and analytical systems as well as software and diagnostic models are also provided.Type: GrantFiled: June 30, 2008Date of Patent: March 4, 2014Assignee: Vermillion, Inc.Inventors: Brian C. Mansfield, Ping F. Yip, Suraj Amonkar, Greg P. Bertenshaw
-
Patent number: 8664359Abstract: The invention is related to isoforms of components of transcription factor complexes that are specifically expressed in cancer cells. These isoforms can be used as biomarkers for detection, diagnosis, prognosis and monitoring of treatments of cancer, and as drug targets of pharmaceutical compositions for the treatment of various cancers expressing the targeted isoforms. Methods, molecules, materials and kits for these uses are disclosed.Type: GrantFiled: June 3, 2008Date of Patent: March 4, 2014Assignee: OncoTx, Inc.Inventors: Anna Kazantseva, Jekaterina Kazantseva
-
Patent number: 8664360Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.Type: GrantFiled: December 20, 2011Date of Patent: March 4, 2014Assignee: Bristols-Myers Squibb CompanyInventors: Glen Eugene Mikesell, Han Chang, Robert James Peach
-
Patent number: 8664361Abstract: Soy products or compositions are treated with a food grade iodate compound or a cystine compound to reduce levels of methanethiol, sulfites and sulfite free-radicals, sulfate free radicals and other free radicals generated from sulfite free radicals in the soy products or compositions by 1% to 95%.Type: GrantFiled: September 7, 2006Date of Patent: March 4, 2014Assignee: University of Kentucky Research FoundationInventor: William L. Boatright
-
Patent number: 8664362Abstract: An isolated anti-properdin antibody or antigen binding portion thereof includes a heavy chain variable domain including the 3CDRs in SEQ ID NO: 1 and light chain variable domain including the 3 CDRS in SEQ ID NO: 9.Type: GrantFiled: March 10, 2011Date of Patent: March 4, 2014Assignee: Novelmed TherapeuticsInventor: Rekha Bansal
-
Patent number: 8664363Abstract: Provided herein are chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7, which comprise human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and light chain variable region (“VK”). The FW regions may contain one or more backmutations in which a human FW residue is exchanged for the corresponding residue present in the parental mouse heavy or light chain. The human or humanized VH framework regions may comprise one or more of the following residues: a valine at position 24 of FW1, a glycine at position 49 of FW2, and an asparagine at position 73 of FW3, numbered according to Kabat. Further provided are pharmaceutical and immunotherapeutic compositions, and methods using anti-CD22 antibodies that preferably mediate human ADCC, CDC, and/or apoptosis for: the treatment of B cell diseases in humans, including B cell malignancies, autoimmune disease, GVHD, humoral rejection, and post-transplantation lymphoproliferative disorder.Type: GrantFiled: February 28, 2013Date of Patent: March 4, 2014Assignee: MedImmune, LLCInventors: Tarran Jones, David G. Williams
-
Patent number: 8664364Abstract: Provided are biosensors, compositions comprising biosensors, and methods of using biosensors in living cells and organisms. The biosensors are able to be selectively targeted to certain regions or structures within a cell. The biosensors may provide a signal when the biosensor is targeted and/or in response to a property of the cell or organism such as membrane potential, ion concentration or enzyme activity.Type: GrantFiled: January 24, 2008Date of Patent: March 4, 2014Assignee: Carnegie Mellon UniversityInventors: Brigitte F. Schmidt, Christopher S. Szent-Gyorgyi, Alan S. Waggoner, Peter B. Berget, Marcel P. Bruchez, Jonathan W. Jarvik
-
Patent number: 8664365Abstract: The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.Type: GrantFiled: October 14, 2010Date of Patent: March 4, 2014Assignee: KaloBios Pharmaceuticals, Inc.Inventors: Kenneth Luehrsen, David Martinez, Christina Yi, Christopher R. Bebbington, Geoffrey T. Yarranton
-
Patent number: 8664366Abstract: The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.Type: GrantFiled: January 9, 2009Date of Patent: March 4, 2014Assignee: Apogenix GmbHInventors: Oliver Hill, Marcus Branschaedel, Christian Gieffers, Meinolf Thiemann
-
Patent number: 8664367Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.Type: GrantFiled: March 20, 2013Date of Patent: March 4, 2014Assignee: AbbVie, Inc.Inventors: Chengbin Wu, Dominic J. Ambrosi, Chung-ming Hsieh, Tariq Ghayur
-
Patent number: 8664368Abstract: The present invention provides a fully human anti-VEGF monoclonal antibody, the preparation method and use thereof. The fully human anti-VEGF monoclonal antibody is obtained by using antibody phage display technology, which has higher antibody affinity and stronger capacity for inhibiting tumor cell proliferation in comparison with humanized antibody bevacizumab, and can be used to prepare anti-tumor medicines.Type: GrantFiled: April 16, 2010Date of Patent: March 4, 2014Assignee: Shanghai Biomabs Pharmaceuticals Co., Ltd.Inventors: Shuhui Wang, Chuan Li, Ying Kan, Xin Tong
-
Patent number: 8664369Abstract: The invention relates to liquid pharmaceutical formulations of luteinizing hormone (LH) for single- or multi-dose administration.Type: GrantFiled: October 29, 2008Date of Patent: March 4, 2014Assignee: Merck Serono S.A.Inventors: Rita Agostinetto, Fabrizio Samaritani, Alessandra Del Rio, Joel Richard
-
Patent number: 8664370Abstract: The invention relates to a process for preparing silicon-containing azodicarbamides of the general formula (I) (R1)3-a(R2)aSi—RI—NH—C(O)—N?N—C(O)—NH—RI—Si(R1)3-a(R2)a (I), by reaction of azobiscarboxy compounds of the general formula II R3—X1—C(O)—N?N—C(O)—X1—R4 (II) with aminosilanes of the general formula III (R1)3-a(R2)aSi—RI—NH2 (III).Type: GrantFiled: March 11, 2011Date of Patent: March 4, 2014Assignee: Evonik Degussa GmbHInventors: Karsten Korth, Julia Keck, Susann Witzsche, Oliver Klockmann, Jaroslaw Monkiewicz, Christian Springer
-
Patent number: 8664371Abstract: Rinsable dyes with improved fugitivity are formulated by attaching dyestuff compounds with amine-capped sulfonic solubilizing groups to commercially available ethoxylated aniline, so that the surfactant effect of the ethoxylated aniline counteracts the substantivity of the dyestuff compound, while the neutralization of the sulfonic solubilizing groups reduces substantivity.Type: GrantFiled: December 2, 2011Date of Patent: March 4, 2014Assignee: Spectra Colors Corp.Inventors: Mark Berenfeld, Sal Harfouch, Peter Caputo
-
Patent number: 8664372Abstract: In preparing a glycoside compound from (a) a furanose compound or pyranose compound, and (b) an alcohol compound, a process for preparing a glycoside compound in which glycosidic bond locates selectively trans form relative to C-2 hydroxyl group, the process comprising using a furanose compound wherein the hydroxyl at the 2-position may have a substituent protected with a group A, or a pyranose compound which may have a substituent wherein R2 and R3 are the same or different and are each alkyl having 1 to 4 carbon atoms or aryl having or not having a substituent, or R2 and R3 are combined to form alkylene having 2 to 4 carbon atoms (the alkylene may be substituted with alkyl having 1 to 4 carbon atoms, or may have intervening phenylene), and m and n are each an integer of 0 or 1.Type: GrantFiled: May 22, 2012Date of Patent: March 4, 2014Assignee: Glytech, Inc.Inventor: Shigeru Yamago
-
Patent number: 8664373Abstract: The present invention provides a low-cost, efficient method for producing a glycolipid biosurfactant, in particular, lactonic sophorose lipids. This method is characterized by culturing a microorganism capable of producing the biosurfactant under limited oxygen supply. The present invention enables preferential production of lactonic sophorose lipids and facilitates recovery of the lactonic sophorose lipids in a solid form. Further, the present invention enables production of high purity acidic sophorose lipids by hydrolyzing high purity lactonic sophorose lipids produced by the above method. The present invention also provides lactonic sophorose lipids that possess strong antibacterial and antifungal activities, and an antibacterial and/or antifungal agent containing the sophorose lipids.Type: GrantFiled: October 23, 2009Date of Patent: March 4, 2014Assignee: Kaneka CorporationInventors: Satohiro Yanagisawa, Shigeru Kawano, Yoshihiko Yasohara
-
Patent number: 8664374Abstract: This invention is directed to methods for recombinant polypeptide production and, in particular, methods and products for the production of recombinant polypeptides in ciliates.Type: GrantFiled: September 20, 2011Date of Patent: March 4, 2014Assignee: Tetragenetics, Inc.Inventors: Paul Colussi, Donna Cassidy-Hanley, Theodore G. Clark
-
Patent number: 8664375Abstract: The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.Type: GrantFiled: December 14, 2010Date of Patent: March 4, 2014Assignee: Alcon Research, Ltd.Inventor: Jon E. Chatterton
-
Patent number: 8664376Abstract: What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1—2 (SEQ ID NOS: 60 and 127), SERPINH1—45a (SEQ ID NOS: 98 and 165), and SERPINH1—51 (SEQ ID NOS: 101 and 168), and drug carrier comprising a mixture of a retinoid and a lipid vesicle, and methods of using these pharmaceutical compositions to treat a disease associated with hsp47 espresssion, including fibrosis.Type: GrantFiled: June 8, 2012Date of Patent: March 4, 2014Assignee: Nitto Denko CorporationInventors: Yoshiro Niitsu, Victor Knopov, Joseph E. Payne, Richard P. Witte, Mohammad Ahmadian, Loren A. Perelman, Violetta Akopian, Yasunobu Tanaka, Elena Feinstein, Sharon Avkin-Nahum, Hagar Kalinski, Igor Mett, Kenjiro Minomi, Wenbin Ying, Yun Liu
-
Patent number: 8664377Abstract: A method and apparatus for efficiently isolating nucleic acids from a nucleic acid-containing sample.Type: GrantFiled: August 9, 2010Date of Patent: March 4, 2014Assignee: Samsung Electronics Co., Ltd.Inventors: Kyu-youn Hwang, Joon-ho Kim, Kak Namkoong
-
Patent number: 8664378Abstract: The present invention solves the problem of isolating nucleic acids from cells in the presence of the growth medium. The invention is particularly useful for isolating extrachromosomal replicons such as plasmids. Cells are lysed in the presence of the medium in which they were grown and nucleic acids are isolated using a pipette tip column. A liquid handling robot can be used to isolate nucleic acids from multiple samples simultaneously without the need for human intervention.Type: GrantFiled: September 30, 2011Date of Patent: March 4, 2014Assignee: PhyNexus, Inc.Inventors: Chris Suh, Lee Hoang, Douglas T. Gjerde
-
Patent number: 8664379Abstract: The present invention relates to sodium channel inhibitors of Formula I: in which R1, R2, R3, R4, R5, R6, and R7 are as defined above, and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes.Type: GrantFiled: December 6, 2012Date of Patent: March 4, 2014Assignee: Gilead Sciences, INc.Inventors: Matthew Abelman, Nancy Chu, Robert H. Jiang, Kwan Leung, Jeff Zablocki
-
Patent number: 8664380Abstract: Compounds represented by the formulas wherein each symbol is as defined in the specification, and a prodrug thereof have a superior renin inhibitory activity, and are useful as agents for the prophylaxis or treatment of hypertension, various organ damages attributable to hypertension and the like.Type: GrantFiled: June 17, 2009Date of Patent: March 4, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Takanobu Kuroita, Yasuhiro Imaeda, Kouichi Iwanaga, Naohiro Taya, Hidekazu Tokuhara
-
Patent number: 8664381Abstract: The present invention relates to a process for the purification of amorolfine hydrochloride by means of a reversed-phase preparative high performances liquid chromatography (prep-HPLC) said method starting from a crude Amorolfine hydrochloride having purity higher than 90% and containing Bepromoline hydrochloride <5% and Fenpropimorf <3%. The process involves the use of a mobile phase comprising water and an organic solvent under isocratic conditions.Type: GrantFiled: February 18, 2010Date of Patent: March 4, 2014Assignee: SYNTECO S.p.A.Inventors: Roberto Angeli, Marco Possenti, Salvatore Demartis
-
Patent number: 8664382Abstract: The present invention relates to pharmaceutical compositions comprising metal phthalocyanine analogues of formula (I) and metal chelating compounds having a good bioavailability and enhanced photoinactivation properties against Gram negative bacteria; and to their use for in vivolex vivo applications, such as blood and blood derivatives sterilization.Type: GrantFiled: April 17, 2003Date of Patent: March 4, 2014Assignee: Molteni Therapeutics S.r.l.Inventors: Gabrio Roncucci, Donata Dei, Giacomo Chiti, Lia Fantetti, Francesco Giuliani, Giulio Jori, Gian Maria Rossolini
-
Patent number: 8664383Abstract: Disclosed is an organometallic complex capable of variable phosphorescence characteristics and yellow emission at high luminance The organometallic complex has a structure represented by a formula (G6), where at least one of R4, R5, R6, and R7 is a phenoxy group, M is a Group 9 metal or a Group 10 metal, and L is a monoanionic ligand.Type: GrantFiled: September 23, 2011Date of Patent: March 4, 2014Assignee: Semiconductor Energy Laboratory Co., Ltd.Inventors: Hideko Inoue, Nobuharu Ohsawa, Satoko Shitagaki, Satoshi Seo
-
Patent number: 8664384Abstract: The use of N6-(ferrocenmethyl)quinazoline-2,4,6-triamine (H2), its derivatives, and prodrugs that present antimicrobial (antibiotic, microbicide), antiparasitic (parasiticide), antiprotozoal (protozoacide), and antileishmanial (leishmanicide) activities, as well as its use as a drug in vertebrates (humans and animals).Type: GrantFiled: February 21, 2011Date of Patent: March 4, 2014Assignee: Norma del Carmen Galindo SevillaInventors: Norma del Carmen Galindo Sevilla, Francisco Hernández Luis
-
Patent number: 8664385Abstract: A family of three 8-alkyl boron dipyrromethenes 1, 2, and 3 has been prepared. These compounds are characterized by emission in the green region of the electromagnetic radiation spectrum and exhibit an almost double laser efficiency than other commercial dyes and much greater photostability. The 8-alkyl boron dipyrromethenes are prepared by catalytic hydrogenation (reduction) of the corresponding 8-alkenyl boron dipyrromethenes, which are obtained by Liebeskind-Srogl coupling of thiomethylboron dipyrromethene with an alkenyl boronic acid.Type: GrantFiled: September 30, 2010Date of Patent: March 4, 2014Assignee: Universidad de GuanajuatoInventors: Eduardo Peña Cabrera, Ismael Javier Arroyo Cordova, Fabiola Irene Lopez Vallejo
-
Patent number: 8664386Abstract: Methods for isolating 9-{(R)-2-[((S)-{[(S)-1-(isopropoxycarbonyl)ethyl]amino}phenoxyphosphinyl)methoxy]propyl}adenine (compound 16): a method for preparing, in high diastereomeric purity, intermediate compounds 13 and 15: and a method for preparing intermediate compound 12: 9-{(R)-2-[((S)-{[(S)-1-(isopropoxycarbonyl)ethyl]amino}phenoxyphosphinyl)methoxy]propyl}adenine has anti-viral properties.Type: GrantFiled: October 3, 2012Date of Patent: March 4, 2014Assignee: Gilead Sciences, Inc.Inventors: Denise A. Colby, Andrew Anthony Martins, Benjamin James Roberts, Robert William Scott, Nicole S. White
-
Patent number: 8664387Abstract: The present invention is directed to quinolinone-pyrazolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.Type: GrantFiled: December 9, 2010Date of Patent: March 4, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Ronald K. Chang, Thomas J. Greshock
-
Patent number: 8664388Abstract: The present invention relates to substituted amino-quinazolinones of general formula (I) wherein the groups R1 to R14 and A, are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.Type: GrantFiled: June 14, 2012Date of Patent: March 4, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Klaus Fuchs, Niklas Heine, Christian Eickmeier, Sandra Handschuh, Cornelia Dorner-Ciossek, Stefan Hoerer
-
Patent number: 8664389Abstract: The present invention relates to an improved and novel process for the preparation of high purity crystalline base of Lapatinib of formula-(1) having chemical name N-{3-chloro-4-[(3-fluorobenzyloxy]phenyl}-6-[5-({[2-(methanesulfonyl)ethyl]amino}methyl]-2-furyl]-4-quin-azolinamine and its pharmaceutically acceptable salts. The present invention further relates to intermediates according to formula (8) and formula (9) used in this process.Type: GrantFiled: August 12, 2009Date of Patent: March 4, 2014Assignee: Natco Pharma LimitedInventors: Ramanadham Jyothi Prasad, Bhujanga Rao Adibhatla Kali Satya, Nannapaneni Venkaiah Chowdary
-
Patent number: 8664390Abstract: The present invention relates to an improved process for the preparation of bosentan. In particular it relates to a process for preparing bosentan substantially free from the dimer impurity of formula (II) and the 6-hydroxy impurity of formula (III). The invention also relates to a pharmaceutical composition comprising bosentan and its use in the treatment of endothelin-receptor mediated disorders.Type: GrantFiled: June 27, 2008Date of Patent: March 4, 2014Assignee: Generics (UK) LimitedInventors: Abhay Gaitonde, Bindu Manojkumar, Sandeep Sonawane, Dattatrey Kokane, Sandeep Mekde, Dattatraya Shinde, Prakash Bansode